Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jul;36(1):51–56. doi: 10.1111/j.1365-2125.1993.tb05891.x

A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

J C Stiekema 1, J M Van Griensven 1, T G Van Dinther 1, A F Cohen 1
PMCID: PMC1364554  PMID: 8396956

Abstract

1. The anti-clotting effects after intravenous administration of three low molecular weight (LMW) heparins, Fragmin (KABI 2165), Fraxiparine (CY 216), Clexane (PK 10169) and the LMW mixture of glycosaminoglycuronans Orgaran (Org 10172) were compared in a randomized cross-over study in 12 healthy male volunteers. 2. The time courses of the anti-Xa activity of Fragmin, Fraxiparine and Clexane (five subjects) were best fitted by a monoexponential function and had comparable half-lives of 1.9 h, 2.3 h and 2.8 h, respectively. The time courses of the anti-Xa activity of Orgaran and Clexane (four subjects) were described by a biexponential function with terminal half-lives of 56.8h and 27.7 h, respectively. They were longer than those of Fraxiparine and Fragmin. Orgaran injection was associated with a significantly smaller 'clearance' (0.8 +/- 0.2 l h-1) of the plasma anti-Xa activity compared with Fragmin (2.0 +/- 0.5), Fraxiparine (1.7 +/- 0.5) and Clexane (1.6 +/- 0.5). 3. In comparison with the three LMW heparins, the terminal half-life of plasma anti-IIa activity after Orgaran was longer and the 'clearance' of Orgaran was lower than that after Clexane. The area under the curve of the plasma anti-IIa activity after administration of Orgaran was negligible compared with that obtained after injection of the LMW heparins. 4. Orgaran caused the smallest and Fragmin the greatest prolongation of the activated partial thromboplastin time (Orgaran 5.8 +/- 1.2 s vs Fragmin 18.5 +/- 5.2 s) and the thrombin clotting time (Orgaran 2.9 +/- 1.7 s vs Fragmin 47.8 +/- 0.9 s).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bara L., Billaud E., Gramond G., Kher A., Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985 Sep 1;39(5):631–636. doi: 10.1016/0049-3848(85)90244-0. [DOI] [PubMed] [Google Scholar]
  2. Bradbrook I. D., Magnani H. N., Moelker H. C., Morrison P. J., Robinson J., Rogers H. J., Spector R. G., Van Dinther T., Wijnand H. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987 Jun;23(6):667–675. doi: 10.1111/j.1365-2125.1987.tb03100.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bratt G., Törnebohm E., Widlund L., Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986 Jun 1;42(5):613–620. doi: 10.1016/0049-3848(86)90340-3. [DOI] [PubMed] [Google Scholar]
  4. Dawes J., Bara L., Billaud E., Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986;16(2):116–122. doi: 10.1159/000215281. [DOI] [PubMed] [Google Scholar]
  5. Fernandez F. A., Buchanan M. R., Hirsh J., Fenton J. W., 2nd, Ofosu F. A. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemost. 1987 Jun 3;57(3):286–293. [PubMed] [Google Scholar]
  6. Frydman A. M., Bara L., Le Roux Y., Woler M., Chauliac F., Samama M. M. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988 Jul;28(7):609–618. doi: 10.1002/j.1552-4604.1988.tb03184.x. [DOI] [PubMed] [Google Scholar]
  7. Harenberg J., Würzner B., Zimmermann R., Schettler G. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res. 1986 Nov 15;44(4):549–554. doi: 10.1016/0049-3848(86)90333-6. [DOI] [PubMed] [Google Scholar]
  8. Larsen M. L., Abildgaard U., Teien A. N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res. 1978 Aug;13(2):285–288. doi: 10.1016/0049-3848(78)90016-6. [DOI] [PubMed] [Google Scholar]
  9. Levine M. N., Hirsh J., Gent M., Turpie A. G., Leclerc J., Powers P. J., Jay R. M., Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991 Apr 1;114(7):545–551. doi: 10.7326/0003-4819-114-7-545. [DOI] [PubMed] [Google Scholar]
  10. Meuleman D. G., Hobbelen P. M., van Dedem G., Moelker H. C. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res. 1982 Aug 1;27(3):353–363. doi: 10.1016/0049-3848(82)90082-2. [DOI] [PubMed] [Google Scholar]
  11. Ofosu F. A., Modi G. J., Smith L. M., Cerskus A. L., Hirsh J., Blajchman M. A. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 1984 Sep;64(3):742–747. [PubMed] [Google Scholar]
  12. Schoen P., Lindhout T., Franssen J., Hemker H. C. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III--effect of platelet factor 4. Thromb Haemost. 1991 Oct 1;66(4):435–441. [PubMed] [Google Scholar]
  13. Stiekema J. C., Wijnand H. P., Van Dinther T. G., Moelker H. C., Dawes J., Vinchenzo A., Toeberich H. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol. 1989 Jan;27(1):39–48. doi: 10.1111/j.1365-2125.1989.tb05333.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Teien A. N., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977 Mar;10(3):399–410. doi: 10.1016/0049-3848(77)90150-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES